Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab

Similar Items

• Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies
  od: Tan, Shuguang, i dr.
  Izdano: (2016)
• Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy
  od: Liu, Kefang, i dr.
  Izdano: (2017)
• The FG Loop of PD-1 Serves as a “Hotspot” for Therapeutic Monoclonal Antibodies in Tumor Immune Checkpoint Therapy
  od: Chen, Danqing, i dr.
  Izdano: (2019)
• Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies
  od: He, Mengnan, i dr.
  Izdano: (2017)
• Glycosylation-independent binding of monoclonal antibody toripalimab to FG loop of PD-1 for tumor immune checkpoint therapy
  od: Liu, Hongchuan, i dr.
  Izdano: (2019)